FDA Names Arcellx’s Cell Therapy CART-ddBCMA Orphan Drug for Multiple Myeloma
Arcellx’s CART-ddBCMA — a CAR T-cell therapy targeting the BCMA protein — was granted orphan drug status by the U.S.
Margarida Azevedo, — 
Articles by Margarida Azevedo
Empliciti Combo Fails to Stem Progression of Newly Diagnosed Multiple Myeloma
Empliciti (elotuzumab), in combination with Revlimid (lenalidomide) and dexamethasone, did not significantly extend the time people with multiple myeloma…
Amgen to Present New Data on Kyprolis, a Multiple Myeloma Treatment, at EHA 2016
Amgen announced it will present new data on its cancer portfolio at the 21st Congress of the European Hematology (EHA) Association taking place next month in Copenhagen. The…
Ongoing Phase 3 Study Finds Daratumumab Improves Survival in Advanced Multiple Myeloma Patients
Genmab has announced positive results from its Phase 3 POLLUX study investigating the efficacy of daratumumab, in combination with lenalidomide and dexamethasone, to treat patients with…
Stem Cell Transplantation to Treat Myeloma Patients Highlighted in Studies
Ajai Chari, MD, director of clinical research in the Multiple Myeloma Program at the Icahn School of Medicine at Mount Sinai in New York, and Navneet Majhail,…
Leisure-Time Physical Activity Associated with Lower Cancer Risk, Including Myeloma
Leisure-time physical activity is associated with a lower risk for many types of cancer, including a 17 percent lower risk for myeloma. These key findings were independent of…
Researchers Develop New Animal Model of Multiple Myeloma
Researchers in the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have developed a new animal model of multiple myeloma,…
Disrupting Specific Protein May Be Effective Multiple Myeloma Treatment Strategy
Researchers at Buffalo, New York-based Roswell Park Cancer Institute revealed that knocking down individual RabGTPases (Rab) proteins in myeloma cells was sufficient to disrupt the trafficking of…
MedImmune’s Antibody Therapy Seen to Effectively Reduce Cancer Stem Cells in Most Newly Diagnosed Multiple Myeloma Patients
A research team led by William Matsui, MD, and Carol Ann Huff, MD, with the Johns Hopkins Kimmel Cancer Center, has found that MedImmune’s novel MEDI-551 antibody treatment…